StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) shareholders

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
73M of 54M shares
Institutional holders
126
56 new, 27 sold out
Net institutional buying
41M
In Q2 2026
Insider trades, 12 months
0 buys · 41 sales
Net sold $8.34M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Commodore Capital LP
Joint filing with Commodore Capital Master LP (9.90%), Michael Kramarz (9.90%) and 1 more
5,721,1099.90%13G (passive)Jun 11, 2026
FMR LLC
Joint filing with Abigail P. Johnson (9.80%)
5,250,1819.80%13G (passive) amendmentSep 30, 2026
Deep Track Capital, LP
Joint filing with David Kroin (6.87%), Deep Track Biotechnology Master Fund, Ltd. (6.87%)
3,610,0006.87%13G (passive) amendmentJun 30, 2026
Rajeev Shah
Joint filing with Peter Kolchinsky (6.30%), RA Capital Healthcare Fund, L.P. (6.30%) and 1 more
3,483,0996.30%13G (passive) amendmentJun 30, 2026
BlackRock, Inc.3,415,7316.50%13G (passive)Jun 30, 2026
Caligan Partners LP
Joint filing with David Johnson (5.90%)
3,163,8665.90%13G (passive) amendmentJun 30, 2026
David Kroin
Joint filing with Deep Track Biotechnology Master Fund, Ltd. (5.81%), Deep Track Capital, LP (5.81%)
3,055,0275.81%13G (passive)May 22, 2026
TCG Crossover Fund II, L.P.
Joint filing with Chen Yu (7.90%), TCG Crossover GP II, LLC (7.90%)
3,017,1207.90%13G (passive)May 5, 2026
Michael Cho
Joint filing with Affinity Asset Advisors, LLC (5.50%)
2,900,0005.50%13G (passive) amendmentJun 30, 2026
Ortav Yehudai
Joint filing with Trails Edge Biotechnology Master Fund, LP (5.20%), Trails Edge Capital Partners, LP (5.20%)
2,803,7615.20%13G (passive)Oct 22, 2026
Lampert Mark N
Joint filing with Bvf Inc/Il (5.30%), Bvf Partners L P/Il (5.30%)
2,801,5455.30%13G (passive) amendmentJun 30, 2026
Point72 Asset Management, L.P.
Joint filing with Point72 Capital Advisors, Inc. (5.20%), Steven A. Cohen (5.20%)
2,710,8175.20%13G (passive)May 22, 2026
Bvf Inc/Il
Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more
1,904,2579.99%13G (passive) amendmentDec 31, 2025
David Johnson
Joint filing with Caligan Partners LP (7.20%)
1,635,0237.20%13G (passive) amendmentMar 31, 2026
Bvf Partners L P/Il
Joint filing with Bvf Inc/Il (9.99%), Lampert Mark N (9.99%) and 3 more
1,458,1519.99%13G (passive) amendmentSep 30, 2025
Behzad Aghazadeh
Joint filing with Avoro Capital Advisors LLC (5.75%)
1,410,0005.75%13G (passive)Mar 31, 2026
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (9.90%), RA Capital Healthcare Fund, L.P. (9.90%) and 1 more
1,386,1679.90%13G (passive) amendmentSep 30, 2025
Logos Global Master Fund LP
Joint filing with Arsani William (5.60%), Logos GP LLC (5.60%) and 2 more
1,285,0005.60%13G (passive)Mar 26, 2026
Affinity Asset Advisors, LLC
Joint filing with Michael Cho (5.70%)
1,051,0545.70%13G (passive) amendmentJan 22, 2026
Millennium Management LLC
Joint filing with Israel A. Englander (5.00%), Millennium Group Management LLC (5.00%)
934,4295.00%13G (passive)Feb 17, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AVTXValueChange% of portfolio
FMR LLC5,100,2169.51%$94.25M+2,220,7350.00%
BlackRock, Inc.4,365,5538.14%$80.68M+4,038,4710.00%
Nantahala Capital Management, LLC3,724,5006.94%$68.83M+2,489,5001.14%
Deep Track Capital, LP3,610,0006.73%$66.71MNew0.97%
Caligan Partners LP3,163,8665.90%$58.47M+1,528,8432.75%
TCG Crossover Management, LLC3,017,1205.63%$55.76M+2,278,7371.34%
Affinity Asset Advisors, LLC2,900,0005.41%$53.59M+1,559,1602.42%
State Street Corp2,889,2875.39%$53.39M+2,817,6330.00%
Farallon Capital Management LLC2,498,0004.66%$46.16M+1,582,0000.21%
Point72 Asset Management, L.P.2,387,0264.45%$44.11M+1,470,8840.05%
Avoro Capital Advisors LLC2,333,3334.35%$43.12M+923,3330.39%
Vanguard Capital Management LLC2,264,2464.22%$41.84M+1,544,5520.00%
Bvf Inc/Il2,075,5453.87%$38.36M+442,7000.98%
Bank Of America Corp /De/1,913,8293.57%$35.37M+1,270,8290.00%
Adage Capital Partners Gp, L.L.C.1,729,0003.22%$31.95M+875,0000.04%
Soleus Capital Management, L.P.1,654,9783.09%$30.58M+1,213,0001.05%
Braidwell LP1,629,1823.04%$30.11MNew1.11%
Price T Rowe Associates Inc /Md/1,311,7152.45%$24.24MNew0.00%
Alliancebernstein L.P.1,260,6892.35%$23.30MNew0.01%
UBS Group AG1,209,0592.25%$22.34M+67,0790.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202612673M100.0%56 / 4715 / 2750M8M
Q1 20269731M58.2%33 / 3119 / 1916M4M
Q4 20258420M37.1%33 / 2813 / 157M2M
Q3 20256615M28.6%32 / 158 / 28M1M
Q2 2025368M14.6%4 / 912 / 21M1M
Q1 2025348M15.4%5 / 114 / 42M1M
Q4 2024338M14.0%9 / 84 / 52M1M
Q3 2024297M12.4%11 / 31 / 26M0M
Q2 2024211M1.4%7 / 44 / 41M0M
Q1 2024180M0.2%8 / 43 / 20M0M
Q4 2023120M0.0%12 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

100 funds held AVTX in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of AVTXValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF2,029,4923.78%$37.51M0.35%Jun 30, 2026
Vanguard Total Stock Market Index Fund1,675,4983.12%$30.96M0.00%Jun 30, 2026
Fidelity Stock Selector Small Cap Fund1,211,6002.26%$22.11M0.30%Jul 31, 2026
iShares Russell 2000 ETF1,093,3262.04%$20.20M0.02%Jun 30, 2026
Fidelity Series Small Cap Opportunities Fund695,6001.30%$12.69M0.27%Jul 31, 2026
Fidelity Advisor Biotechnology Fund639,7001.19%$11.67M0.53%Jul 31, 2026
Vanguard Extended Market Index Fund537,2411.00%$9.93M0.01%Jun 30, 2026
AB Small Cap Growth Portfolio486,5560.91%$8.99M0.29%Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.471,8220.88%$8.72M0.07%Jun 30, 2026
Fidelity Small Cap Index Fund457,3130.85%$8.35M0.02%Jul 31, 2026
Fidelity Small Cap Discovery Fund384,6710.72%$7.02M0.31%Jul 31, 2026
Fidelity Series Small Cap Discovery Fund330,4700.62%$6.03M0.31%Jul 31, 2026
BlackRock Health Sciences Opportunities Portfolio299,5850.56%$4.78M0.08%May 29, 2026
T. Rowe Price New Horizons Fund, Inc.287,6630.54%$5.32M0.04%Jun 30, 2026
Fidelity Series Small Cap Core Fund212,2000.40%$3.87M0.25%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Garry Arthur NeilChief Executive Officer, Director190,3140.35%May 26, 2026
Christopher Ryan SullivanChief Financial Officer39,9000.07%Sep 18, 2026
Mittie DoyleChief Medical Officer51,7760.10%Sep 1, 2026
Jennifer RileyChief Strategy Officer37,0410.07%Aug 12, 2026
Paul VarkiChief Legal Officer32,5760.06%Jun 12, 2026
Taylor BoydChief Business Officer––Mar 2, 2026
Rita JainDirector––Oct 2, 2026
Ron M. PhilipDirector––Oct 2, 2026
Kevin Robert LindDirector––Oct 2, 2026
Samantha TruexDirector6,3330.01%Jun 4, 2026
Gilla KaplanDirector6,3330.01%Jun 4, 2026
Aaron KantoffDirector6,3330.01%Jun 4, 2026
Michael Thomas HeffernanDirector––Jun 4, 2026
Mitchell ChanDirector3,1660.01%May 7, 2026
Jonathan GoldmanDirector3,1660.01%Mar 31, 2026
June Sherie AlmenoffDirector4,1670.01%Jun 18, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Christopher Ryan Sullivan
Chief Financial Officer
Sep 16, 2026Sale(10b5-1 plan)−12,394$16.33$202.39K39,900
Christopher Ryan Sullivan
Chief Financial Officer
Sep 16, 2026Option exercise+12,394$9.88$122.45K52,294
Christopher Ryan Sullivan
Chief Financial Officer
Sep 10, 2026Sale(10b5-1 plan)−10,185$17.62$179.46K39,900
Christopher Ryan Sullivan
Chief Financial Officer
Sep 10, 2026Option exercise+10,185$8.04$81.89K50,085
Mittie Doyle
Chief Medical Officer
Aug 28, 2026Sale(10b5-1 plan)−679$20.00$13.58K51,776
Mittie Doyle
Chief Medical Officer
Aug 28, 2026Option exercise+679$8.04$5.46K52,455
Christopher Ryan Sullivan
Chief Financial Officer
Aug 18, 2026Option exercise+31,031$9.88$306.59K70,931
Christopher Ryan Sullivan
Chief Financial Officer
Aug 18, 2026Sale(10b5-1 plan)−31,031$20.05$622.17K39,900
Mittie Doyle
Chief Medical Officer
Aug 17, 2026Option exercise+1,000$12.65$12.65K52,776
Mittie Doyle
Chief Medical Officer
Aug 17, 2026Sale(10b5-1 plan)−1,000$20.00$20.00K51,776
Christopher Ryan Sullivan
Chief Financial Officer
Aug 17, 2026Option exercise+37,945$9.88$374.90K78,718
Christopher Ryan Sullivan
Chief Financial Officer
Aug 17, 2026Option exercise+2,876$9.88$28.41K81,594
Christopher Ryan Sullivan
Chief Financial Officer
Aug 17, 2026Sale(10b5-1 plan)−37,945$19.85$753.21K43,649
Christopher Ryan Sullivan
Chief Financial Officer
Aug 17, 2026Sale(10b5-1 plan)−3,749$19.94$74.76K39,900
Jennifer Riley
Chief Strategy Officer
Aug 11, 2026Sale−2,655$19.59$52.01K37,041
Mittie Doyle
Chief Medical Officer
Aug 10, 2026Sale(10b5-1 plan)−679$20.00$13.58K51,776
Mittie Doyle
Chief Medical Officer
Aug 10, 2026Option exercise+679$8.04$5.46K52,455
Mittie Doyle
Chief Medical Officer
Jul 27, 2026Option exercise+1,000$12.65$12.65K52,776
Mittie Doyle
Chief Medical Officer
Jul 27, 2026Sale(10b5-1 plan)−1,000$20.00$20.00K51,776
Mittie Doyle
Chief Medical Officer
Jun 30, 2026Sale(10b5-1 plan)−4,654$20.00$93.08K51,776
Mittie Doyle
Chief Medical Officer
Jun 30, 2026Option exercise+1,779$8.04$14.30K56,430
Mittie Doyle
Chief Medical Officer
Jun 30, 2026Option exercise+2,875$12.65$36.37K54,651
Mittie Doyle
Chief Medical Officer
Jun 23, 2026Option exercise+1,450$8.04$11.66K53,226
Mittie Doyle
Chief Medical Officer
Jun 23, 2026Sale(10b5-1 plan)−1,450$18.00$26.10K51,776
Mittie Doyle
Chief Medical Officer
Jun 10, 2026Tax withholding−1,084$13.10$14.20K51,776
Jennifer Riley
Chief Strategy Officer
Jun 10, 2026Tax withholding−588$13.10$7.70K39,696
Paul Varki
Chief Legal Officer
Jun 10, 2026Tax withholding−1,081$13.10$14.16K32,576
Christopher Ryan Sullivan
Chief Financial Officer
Jun 10, 2026Tax withholding−138$13.10$1.81K40,773
Mittie Doyle
Chief Medical Officer
May 28, 2026Sale(10b5-1 plan)−679$16.00$10.86K47,122
Mittie Doyle
Chief Medical Officer
May 28, 2026Option exercise+679$8.04$5.46K47,801
Paul Varki
Chief Legal Officer
May 21, 2026Award+24,300––27,934
Garry Arthur Neil
Chief Executive Officer, Director
May 21, 2026Award+100,200––190,314
Jennifer Riley
Chief Strategy Officer
May 21, 2026Award+34,200––36,855
Christopher Ryan Sullivan
Chief Financial Officer
May 21, 2026Award+39,900––40,323
Mittie Doyle
Chief Medical Officer
May 21, 2026Award+43,500––47,122
Mittie Doyle
Chief Medical Officer
May 15, 2026Option exercise+3,000$12.65$37.95K6,622
Mittie Doyle
Chief Medical Officer
May 15, 2026Sale(10b5-1 plan)−3,000$18.76$56.28K3,622
Christopher Ryan Sullivan
Chief Financial Officer
May 7, 2026Option exercise+18,606$9.88$183.83K19,029
Christopher Ryan Sullivan
Chief Financial Officer
May 7, 2026Sale(10b5-1 plan)−18,606$24.12$448.78K423
Paul Varki
Chief Legal Officer
May 6, 2026Sale(10b5-1 plan)−22,839$21.22$484.64K13,287
Paul Varki
Chief Legal Officer
May 6, 2026Option exercise+62,500$13.43$839.38K66,134
Paul Varki
Chief Legal Officer
May 6, 2026Sale(10b5-1 plan)−400$23.71$9.48K3,634
Paul Varki
Chief Legal Officer
May 6, 2026Sale(10b5-1 plan)−9,253$22.70$210.04K4,034
Paul Varki
Chief Legal Officer
May 6, 2026Sale(10b5-1 plan)−5,196$19.78$102.78K36,126
Paul Varki
Chief Legal Officer
May 6, 2026Sale(10b5-1 plan)−37,375$18.91$706.76K41,322
Paul Varki
Chief Legal Officer
May 6, 2026Option exercise+12,563$8.04$101.01K78,697
Mittie Doyle
Chief Medical Officer
May 6, 2026Option exercise+28,650$8.04$230.35K110,177
Mittie Doyle
Chief Medical Officer
May 6, 2026Option exercise+77,905$12.65$985.50K81,527
Mittie Doyle
Chief Medical Officer
May 6, 2026Sale(10b5-1 plan)−10,058$22.88$230.13K3,622
Mittie Doyle
Chief Medical Officer
May 6, 2026Sale(10b5-1 plan)−27,538$18.03$496.51K82,639
Mittie Doyle
Chief Medical Officer
May 6, 2026Sale(10b5-1 plan)−5,000$19.65$98.25K77,639
Mittie Doyle
Chief Medical Officer
May 6, 2026Sale(10b5-1 plan)−44,944$21.20$952.81K32,695
Mittie Doyle
Chief Medical Officer
May 6, 2026Sale(10b5-1 plan)−19,015$22.41$426.13K13,680
Mitchell Chan
Director
May 6, 2026Sale(10b5-1 plan)−3,167$22.88$72.46K3,166
Christopher Ryan Sullivan
Chief Financial Officer
May 6, 2026Option exercise+47,000$8.04$377.88K47,423
Christopher Ryan Sullivan
Chief Financial Officer
May 6, 2026Sale(10b5-1 plan)−13,834$18.55$256.62K33,589
Christopher Ryan Sullivan
Chief Financial Officer
May 6, 2026Sale(10b5-1 plan)−8,900$22.57$200.87K423
Christopher Ryan Sullivan
Chief Financial Officer
May 6, 2026Sale(10b5-1 plan)−12,347$19.28$238.05K21,242
Christopher Ryan Sullivan
Chief Financial Officer
May 6, 2026Sale(10b5-1 plan)−2,700$20.76$56.05K18,542
Christopher Ryan Sullivan
Chief Financial Officer
May 6, 2026Sale(10b5-1 plan)−9,219$21.37$197.01K9,323

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
16.73%
9M shares short
Days to cover
2.1
At 4M shares a day
Change since last report
-25.5%
From 12M shares
Short volume, 20 days
32.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Avalo Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 98,952 shares on Aug 26, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Christopher Ryan Sullivan
Officer
Aug 18, 202631,031$622.22KAug 18, 2026Exercise of Options Under a Registered Plan
Christopher Ryan Sullivan
Officer
Aug 17, 20263,749$74.76KAug 17, 2026Exercise of Options Under a Registered Plan
Christopher Ryan Sullivan
Officer
Aug 17, 202670,709$1.39MAug 17, 2026Exercise of Stock Options
Mittie Doyle
Officer
Aug 17, 20265,037$98.67KAug 17, 2026Exercise of Stock Options
Jennifer Riley
Officer
Aug 11, 20262,655$52.01KAug 11, 2026Shares Purchased Through Employee Stock Purchase Plan
Mittie Doyle
Officer
Aug 10, 2026679$12.44KAug 10, 2026Exercise of Stock Options
Jonathan Goldman
Director
Jun 2, 202642,833$616.23KJun 2, 2026Exercise of options under a registered plan
Christopher Ryan Sullivan
Officer
May 7, 202618,606$405.80KMay 7, 2026Exercise of Stock Options
Mitchell Chan
Director
May 6, 20263,167$51.50KMay 6, 2026Restricted Stock Units
Paul Varki
Officer
May 6, 202692,771$1.51MMay 6, 2026Exercise of Stock Options
Christopher Ryan Sullivan
Officer
May 6, 202647,000$764.22KMay 6, 2026Exercise of Stock Options
Mittie Doyle
Officer
May 6, 202654,508$886.30KMay 6, 2026Exercise of Stock Options
Christopher Ryan Sullivan
Officer
Apr 29, 202616,915$217.53KApr 29, 2026Restricted Stock Units
Mittie Doyle
Officer
Apr 6, 202665,800$1.17MApr 6, 2026Exercise of Stock Options
Christopher Ryan Sullivan
Officer
Apr 1, 202615,959$238.27KApr 1, 2026Restricted Stock Units

See a number that looks wrong?